Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
he present art of drug discovery and design of new drugs is based on suicidal irreversible inhibitors. Covalent inhibition is the strategy that is used to achieve irreversible inhibition. Irreversible inhibitors interact with their targets in a time-dependent fashion, and the reaction proceeds to completion rather than to equilibrium. Covalent inhibitors possessed some significant advantages over non-covalent inhibitors such as covalent warheads can target rare, non-conserved residue of a particular target protein and thus led to development of highly selective inhibitors, covalent inhibitors can be effective in targeting proteins with shallow binding cleavage which will led to development of novel inhibitors with increased potency than non-covalent inhibitors. Several computational approaches have been developed to simulate covalent interactions; however, this is still a challenging area to explore. Covalent molecular docking has been recently implemented in the computer-aided drug design workflows to describe covalent interactions between inhibitors and biological targets. In this review we highlight: (i) covalent interactions in biomolecular systems; (ii) the mathematical framework of covalent molecular docking; (iii) implementation of covalent docking protocol in drug design workflows; (iv) applications covalent docking: case studies and (v) shortcomings and future perspectives of covalent docking. To the best of our knowledge; this review is the first account that highlights different aspects of covalent docking with its merits and pitfalls. We believe that the method and applications highlighted in this study will help future efforts towards the design of irreversible inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Examples of covalent inhibitors including their protein target(s) with active-site nucleophile: (A) aspirin; (B) neratinib; (C) rivastigmine; (D) Crystal structure of EGFR kinase domain in complex with neratinib, showing the covalent bond between the receptor and the ligand [27].](https://figures.cochat.ai/paper-figures/4c29b35814fb4c5895f870ace31f2ee7/theory-and-applications-of-covalent-docking-in-drug-discovery-merits-and-figure-1.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Due to the increasing interest in covalent drugs, many non-covalent docking programs have developed covalent versions and some new docking programs focused on covalent ligands have been developed (Kumalo et al., 2015; Awoonor-Williams et al., 2017; De Cesco et al., 2017).”
From Empirical scoring functions for structure-based virtual screening: applications, critical aspects, and challenges (2018) · cites this paper as Kumalo et al., 2015
In the citing paper
“However, the majority of covalent algorithms are limited to accurately calculating the binding energy between a nucleophilic protein and an electrophilic small molecule (Fig. 4) [74].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412 · cited 1×
“The most common docking programs and software include Autodock [31], Autodock Vina [32], GOLD [33] and FlexX [34].”
MethodAutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486 · cited 5×
“The most common docking programs and software include Autodock [31], Autodock Vina [32], GOLD [33] and FlexX [34].”
BackgroundMethodInfluentialFriesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051256o · Cited by 6,851 · cited 1×
“com/web/ Autodock [60] Glide [61] CovDock [62]”
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763 · cited 4×
“Zhang et al., reported covalent docking (using GOLD version 4.0) in conjunction with molecular dynamics (MD) simulation (Amber Molecular Dynamics Package version 8.0) to explore the binding mode of peptide aldehyde inhibitors as anti-tumor drugs (Figure 4C,D).”
MethodInfluentialA Fast Flexible Docking Method using an Incremental Construction Algorithm
Rarey, M., Kramer, B., Lengauer, T., & Klebe, G. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0477 · Cited by 2,827 · cited 2×
“The most common docking programs and software include Autodock [31], Autodock Vina [32], GOLD [33] and FlexX [34].”
BackgroundMethodThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“Examples of covalent inhibitors including their protein target(s) with active-site nucleophile: (A) aspirin; (B) neratinib; (C) rivastigmine; (D) Crystal structure of EGFR kinase domain in complex with neratinib, showing the covalent bond between the receptor and the ligand [27].”
BackgroundThe resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873 · cited 3×
“However, not all drugs bind non-covalently to the active site; there are other categories of drugs, namely the covalent drugs [14].”
BackgroundInfluentialAcetylation of prostaglandin synthase by aspirin.
Roth, G. J., Stanford, N., & Majerus, P. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.3073 · Cited by 1,009 · cited 1×
“The earliest example of a covalent drug is aspirin, which was first marketed over a century ago; aspirin covalently modifies cyclooxygenase by inducing the acetylation of a serine residue that is situated in the active site (Figure 1A) [15–18].”
BackgroundAbagyan, R., & Totrov, M. (1994) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.1052 · Cited by 975 · cited 1×
“Abagyan and Totrov developed a 4D-docking protocol for Internal Coordinate Mechanics (ICM), where the receptor conformation is the fourth dimension [63–65].”
MethodDrugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839 · cited 1×
“These types of inhibitors derive their activity from both non-covalent interactions and the formation of the covalent bond between the inhibitor and the target protein [8–13].”
Background
Research works printed but not linked: 1
- Ding, 2002, Computational manufacturing, Prog. Nat. Sci., 12, 641
Cited by
Molecular Docking and Structure-Based Drug Design Strategies
Ferreira, L., Dos Santos, R., Oliva, G., & Andricopulo, A. (2015) · Molecules · doi:10.3390/molecules200713384 · Cited by 2,528
“Recent reports have claimed that approximately one-third of the currently marketed enzyme modulators are covalent inhibitors [88].”
BackgroundGuedes, I. A., Pereira, F. S. S., & Dardenne, L. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01089 · Cited by 331
“Due to the increasing interest in covalent drugs, many non-covalent docking programs have developed covalent versions and some new docking programs focused on covalent ligands have been developed (Kumalo et al., 2015; Awoonor-Williams et al., 2017; De Cesco et al., 2017).”
BackgroundMethodCovalent inhibitors design and discovery.
De Cesco, S., Kurian, J., Dufresne, C., Mittermaier, A. K., & Moitessier, N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.019 · Cited by 315
“The rising interest in covalent drugs has resulted in a surge in the development of docking methods to bolster their discovery and design [108].”
BackgroundDocking Screens for Novel Ligands Conferring New Biology: Miniperspective
Irwin, J. J., & Shoichet, B. K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b02008 · Cited by 277
Molecular Docking for Drug Discovery and Development: A Widely Used Approach but Far from Perfect
Wang, G., & Zhu, W. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0143 · Cited by 175
Metadata
- Authors
- Kumalo, H., Bhakat, S., & Soliman, M.
- Affiliations
- University of KwaZulu-Natal (ZA)
- Corresponding author
- Soliman, Mahmoud
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2015-01-27
- Volume
- 20
- Issue
- 2
- Pages
- 1984-2000
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC6272664
- OpenAlex
- W2029963983
- Cited by
- 158
- References
- 68
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 10 · 2023: 17 · 2022: 11 · 2021: 17 · 2020: 17 · 2019: 11 · 2018: 13 · 2017: 13 · 2016: 19 · 2015: 5
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation
- Inyuvesi Yakwazulu-Natali
- Center for High Performance Computing
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- covalent docking, covalent inhibitors, irreversible inhibition, computer-aided drug design, covalent interactions, protein-ligand binding, covalent warheads, selective inhibitors
- MeSH terms
- Humans, Protein Binding, Software, Thermodynamics, Drug Discovery, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls. https://app.cochat.ai/papers/10.3390/molecules20021984
- The paper
- Kumalo, H., Bhakat, S., & Soliman, M. (2015). Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls. Molecules. https://doi.org/10.3390/molecules20021984
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.